INVESTORS

Investment Opportunities

The Company understands that entry of new and potentially disruptive products into the market is complex and that obtaining the necessary certifications takes time.

The Company has identified various expenditures needed to achieve its Business Plan. From time to time The Company will seek to raise needed funds through Private Placements.

Up to this point (August 2026) The Company has been supported by its Directors and insiders, both financially and by extensive time commitments.

The Company intends to seek a public listing no earlier than 2027/28 on a Canadian stock exchange. This will provide liquidity to current and future shareholders and give the Company better access to funding and strategic partnerships needed for clinical trials.

The Company seeks to achieve a moderate raise of up to $450,000 now to fund it through the next 12 months, for operating, patenting and regulatory filings (including Materials Safety Data Sheets (MSDS), product certifications US FDA and Health Canada), securing trademarks, insurance, and presentation of our work at a major international conference.

An additional raise may be requested if a specific clinical trial needs funding. The Company has identified a team for small-scale single site human trials. Positive results involving human data provides the highest multiplier to a Company’s value, and its shares value. Given such data, EH3 would be on track to become a rapidly scaling, high-value asset, with projected share value multiples indicating significant appreciation potential.

The Company then plans a larger raise prior to its Initial Public Offering (IPO), and at a share price to be determined after current high value research projects have produced initial data.

Qualified investors are invited to contact our CFO, Darren Dingwall, with their expressions of interest in becoming part of our growth.